Izrael - héber - Ministry of Health

sanofi - aventis israel ltd - valproic acid; valproic acid as sodium - טבליות בשחרור ממושך - valproic acid 145 mg; valproic acid as sodium 333 mg - valproic acid

Izrael - héber - Ministry of Health

pfizer pharmaceuticals israel ltd - neisseria meningitidis group a polysaccharide; neisseria meningitidis group c polysaccharide; neisseria meningitidis group w - 135 polysaccharide; neisseria meningitidis group y polysaccharide - אבקה וממס להכנת תמיסה להזרקה - neisseria meningitidis group y polysaccharide 5 mcg; neisseria meningitidis group w - 135 polysaccharide 5 mcg; neisseria meningitidis group c polysaccharide 5 mcg; neisseria meningitidis group a polysaccharide 5 mcg - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - nimenrix is indicated for active immunisation of individuals from the age of 12 months and above against invasive meningococcal diseases caused by neisseria meningitidis group a, c, w-135 and y.

Izrael - héber - Ministry of Health

sanofi - aventis israel ltd - aluminium oxide hydrated 200 mg; dimethicone 25 mg - chewable tablets - combinations - antacid, antiflatulent, relief of sensation of heartburn.

Izrael - héber - Ministry of Health

sanofi - aventis israel ltd - aluminium oxide hydrated 460 mg; magnesium hydroxide 400 mg - suspension - combinations - for heartburn and gastroesophageal reflux.

Izrael - héber - Ministry of Health

sanofi - aventis israel ltd - enoxaparin sodium 100 mg/ml - solution for injection - enoxaparin - treatment of acute st-segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible or not for subsequent coronary angioplasty.

Izrael - héber - Ministry of Health

sanofi - aventis israel ltd - pentoxifylline 400 mg - tablets prolonged release - pentoxifylline - for the improvement of blood flow in the peripheral blood vessels.

Izrael - héber - Ministry of Health

sanofi - aventis israel ltd - ofloxacin 2 mg/ml - solution for infusion - ofloxacin - infections of kidney, urinarty tract, genital organs, respiratory tract, chronic and recurrent ear, nose and throat, skin and soft tissues, bones and joints, bacterial enteritis, abdominal cavity, including pelvis minor and septicemia caused by ofloxacin sensitive microorganisms. prevention of infections in patients with a signifcant reduction of resistance to infections,

Izrael - héber - Ministry of Health

sanofi - aventis israel ltd - levofloxacin as hemihydrate - תמיסה לאינפוזיה - levofloxacin as hemihydrate 5 mg/ml - levofloxacin - levofloxacin - in adults for whom intravenous therapy is considered to be appropriate, tavanic solution for infusion is indicated for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: community- acquired pneumonia, complicated urinary tract infections including pyelonephritis, skin and soft tissue infections.

Izrael - héber - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - pneumococcal vaccine polyvalent - תמיסה להזרקה - pneumococcal vaccine polyvalent 25 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen - pneumococcus, purified polysaccharides antigen - for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.

Izrael - héber - Ministry of Health

sanofi - aventis israel ltd - docetaxel as trihydrate 20 mg / 1 ml - concentrate for solution for infusion - docetaxel - breast cancer: taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.